Entries by Roger Tatoud

18 May 2021 – HIV Vaccine Awareness Day

Today, the Journal of the International AIDS Society (JIAS) commemorates HIV Vaccine Awareness Day and reflects on the long-standing efforts to develop an HIV vaccine and the significance of SARS-CoV-2 vaccine development over the past year for the future of HIV vaccine research.

How HIV Vaccine R&D is enabling the rapid COVID-19 vaccine response

In this presentation, Dr. Roger Tatoud, presents the finding of an investigation led by the Enterprise to identify and characterize the ways in which HIV vaccine R&D has contributed to the early success of the COVID-19 vaccine response, the extent to which it has contributed across various dimensions, and the uniqueness of its contributions relative to other fields.

HIV R4P Virtual News

HIV vaccine highlights and spotlights – To help attendees manage their time and navigate a busy programme, the Enterprise has developed an HIV vaccine R&D roadmap which covers active immunization and  passive immunization with broadly neutralizing antibodies (bNAbs), especially VRC01.

VIDEO recording available – Making mAb Accessible webinar

VIDEO – Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’

The video recording of the Global HIV Vaccine Enterprise and IAVI webinar to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention is now available online.